ImmuCell Corporation (ICCC)
Nasdaq: ICCC · In Vitro & In Vivo Diagnostic Substances · Portland, ME · filing with the SEC since 1995
Who owns ImmuCell Corporation
As filed with the SECHolders of 5% or more
2
Ejnar A. Knudsen III holds 9.21% of Common Stock, $0.10 par value per share, as its SCHEDULE 13D/A filed Nov 20, 2025 says.
Directors and officers
12
report now, of 17 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Ejnar A. Knudsen III
SCHEDULE 13D/A · filed Nov 20, 2025 · Common Stock, $0.10 par value per share
Srk Fund I, LP
SCHEDULE 13D/A · filed Sep 17, 2024 · Common Stock · 5% in May 22, 2024
What ICCC reports owning in othersstakes of 5% or more, and other ties
ImmuCell Corporation reports no stake in another company in the record.
Insider tradesForm 4
0sales
8purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$200,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 19 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Te Boekhorst Paul Francis Olivier | President and CEO | 0 | $0 | 0 | 6 | $200,000 |
| Tomsche David Scott | director | 0 | $0 | 0 | 2 | $0 |